AvalehtBHC • NYSE
add
Bausch Health Companies Inc
Viimane sulgemishind
7,88 $
Tänane vahemik
7,45 $ - 7,80 $
Aasta vahemik
3,96 $ - 11,46 $
Turuväärtus
2,74 mld USD
Keskmine maht
1,27 mln
P/E suhe
-
Dividendimäär
-
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Käive | 2,51 mld | 12,15% |
Põhitegevusega seonduv kulu | 1,27 mld | 13,29% |
Puhastulu | −85,00 mln | 77,51% |
Puhaskasumimarginaal | −3,39 | 79,93% |
Puhaskasum aktsia kohta | 1,12 | 9,34% |
EBITDA | 866,00 mln | 8,93% |
Tõhus maksumäär | −338,10% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 719,00 mln | −5,39% |
Kogu vara | 26,54 mld | −1,94% |
Kõik kohustused | 26,78 mld | −1,89% |
Kogu omakapital | −242,00 mln | — |
Emiteeritud aktsiate arv | 367,80 mln | — |
Hinna ja väärtuse suhe P/B | −2,47 | — |
Varade tasuvus | 5,13% | — |
Kapitali tasuvus | 6,37% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Puhastulu | −85,00 mln | 77,51% |
Põhitegevuse rahakäive | 405,00 mln | 43,62% |
Investeeringute raha | −102,00 mln | 94,60% |
Finantseerimise raha | −189,00 mln | −110,41% |
Raha ja raha ekvivalentide muutus | 127,00 mln | −33,85% |
Tasuta rahavoog | 606,75 mln | 261,43% |
Teave
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.
Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada.
Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Wikipedia
Tegevjuht
Asutatud
1959
Peakontor
Veebisait
Töötajate arv
20 270